Ketamine is detectable in urine for 3–5 days after occasional use and 7–14 days for chronic users. However, the most important fact for anyone concerned about testing: standard 5, 10, and 12-panel workplace drug tests do NOT include ketamine. Detection requires specialized immunoassay or LC-MS/MS testing, which is primarily used in clinical, forensic, and court-ordered monitoring contexts.
Ketamine is metabolized by liver enzymes CYP3A4 and CYP2B6 into norketamine (an active metabolite with approximately 30% of ketamine's potency) and subsequently into dehydronorketamine (inactive). Both norketamine and its metabolites are excreted renally. The parent compound has a short half-life (2–4 hours), but norketamine persists longer, extending the urine detection window beyond what the half-life alone would predict.
Specialized ketamine immunoassay screens use a cutoff of 100–1,000 ng/mL depending on the laboratory protocol. These tests are not included in standard panels and must be specifically ordered. The most common contexts for ketamine-specific testing are: pain management monitoring, ketamine clinic compliance, forensic investigations, and specialized athletic testing.
Chronic ketamine use poses a unique and severe risk: ketamine-induced cystitis (bladder damage). This condition involves inflammation, ulceration, and fibrosis of the bladder wall, leading to severely reduced bladder capacity, painful urination, urinary frequency, and in extreme cases, the need for surgical bladder reconstruction. This damage can be irreversible and is the most serious physical health consequence of regular ketamine use.
No. Standard 5, 10, and even 12-panel drug tests do not include ketamine. Only specialized testing can detect it.
Chronic heavy users: 7–14 days due to accumulation of norketamine metabolites. Occasional users: 3–5 days.
Only on specialized ketamine-specific tests (not standard panels). Provide prescriber documentation to the testing authority if this situation arises.